NCT03619954 is a Phase 1 clinical trial of NK cells infusion in Immunotherapy, sponsored by Anhui Provincial Hospital.

Who is sponsoring NCT03619954?

NCT03619954 is sponsored by Anhui Provincial Hospital.

What drugs are being tested in NCT03619954?

Interventions in NCT03619954: NK cells infusion.

What condition does NCT03619954 study?

NCT03619954 studies Immunotherapy.

Is NCT03619954 still recruiting?

NCT03619954 is currently status unknown. Last updated 8 August 2018.

Last reviewed 2018-08-08 · How we verify

NCT03619954

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

NK Cells Infusion for Advanced Malignancies

Status unknown Phase 1 Last updated 8 August 2018

What this trial tests

Phase 1 trial testing NK cells infusion in Immunotherapy in 50 participants. Status unknown.

Timeline

1 July 2018

Primary endpoint
1 July 2019

1 July 2020

Quick facts

Lead sponsor	Anhui Provincial Hospital
Phase	Phase 1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	50
Start date	1 July 2018
Primary completion	1 July 2019
Estimated completion	1 July 2020
Sites	1 location across China

Drugs / interventions tested

NK cells infusion — full drug profile →

Conditions studied

Immunotherapy — all drugs for Immunotherapy →

Sponsor

Anhui Provincial Hospital

Who can join

Adults 18 to 75, any sex, with Immunotherapy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is designed to explore the safety and efficacy of natural killer (NK) cell infusion as treatment for patients with advanced malignant tumors after multiline therapy, and to evaluate the pharmacokinetics of NK cells in patients

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

NK cell-based cancer immunotherapy: from basic biology to clinical development.
Liu S, Galat V, Galat Y, Lee YKA, et al · · 2021 · cited 504× · PMID 33407739 · DOI 10.1186/s13045-020-01014-w
Influence of the Tumor Microenvironment on NK Cell Function in Solid Tumors.
Melaiu O, Lucarini V, Cifaldi L, Fruci D. · · 2019 · cited 324× · PMID 32038612 · DOI 10.3389/fimmu.2019.03038
Natural Killer Cell Therapy: A New Treatment Paradigm for Solid Tumors.
Oh S, Lee JH, Kwack K, Choi SW. · · 2019 · cited 60× · PMID 31614472 · DOI 10.3390/cancers11101534
Establishment of an efficient ex vivo expansion strategy for human natural killer cells stimulated by defined cytokine cocktail and antibodies against natural killer cell activating receptors.
Nakazawa T, Morimoto T, Maeoka R, Matsuda R, et al · · 2022 · cited 22× · PMID 35919498 · DOI 10.1016/j.reth.2022.07.001
Emerging Approaches for Solid Tumor Treatment Using CAR-T Cell Therapy.
Chung H, Jung H, Noh JY. · · 2021 · cited 18× · PMID 34830003 · DOI 10.3390/ijms222212126

Verify or expand the search:

Other recruiting trials for Immunotherapy

Currently open trials in the same condition.

NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting
NCT07475403 — Urinary Tumor DNA-Guided Systemic Immunotherapy for Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer · Phase 2 · recruiting
NCT07458529 — Neoadjuvant Chemoradiotherapy Plus Tislelizumab With or Without Probio-M9 in pMMR/MSS Locally Advanced Rectal Cancer · Phase 2 · recruiting
NCT07436845 — Impact of Emotional Status on Prognosis of Patients With BCLC Stage B/C Hepatocellular Carcinoma Undergoing Hepatic Arte · recruiting
NCT06671613 — Evaluating a Fasting-mimicking Diet in Combination With Immunotherapy in Patients With Non-small Cell Lung Cancer · NA · recruiting

Other Anhui Provincial Hospital trials

Trials by the same sponsor.

NCT07523464 — Centrally Confined 8Gy/1f to Tumor Core Followed by Concurrent Chemoradiotherapy for Unresectable Stage III NSCLC · Phase 1 · not yet recruiting
NCT07481656 — Effects of Recombinant Human Growth Hormone in Elderly Patients With Moderate to Severe Acute Brain Injury (GH-ABI-RCT) · Phase 4 · not yet recruiting
NCT07462676 — Simultaneous Vs Staged VPS and CP :A Multi-cnter RCT. · NA · not yet recruiting
NCT07211048 — Anti CD19 Gene Therapy for B-cell Lymphoma · NA · recruiting
NCT07279844 — An Open-label, Observational, Long-term Follow-up Study Evaluating the Safety and Efficacy of RGL-193 Putamen Injection · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03619954 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Anhui Provincial Hospital
Last refreshed: 8 August 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03619954.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing